1. Home
  2. TNXP vs III Comparison

TNXP vs III Comparison

Compare TNXP & III Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$12.79

Market Cap

192.9M

Sector

Health Care

ML Signal

HOLD

Logo Information Services Group Inc.

III

Information Services Group Inc.

HOLD

Current Price

$4.14

Market Cap

193.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
III
Founded
2007
2006
Country
United States
United States
Employees
N/A
1500
Industry
Biotechnology: Pharmaceutical Preparations
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
192.9M
193.7M
IPO Year
2008
2006

Fundamental Metrics

Financial Performance
Metric
TNXP
III
Price
$12.79
$4.14
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$5.50
AVG Volume (30 Days)
525.4K
199.4K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
4.46%
EPS Growth
91.75
216.67
EPS
N/A
0.05
Revenue
$13,107,000.00
$192,745,000.00
Revenue This Year
$558.11
$3.85
Revenue Next Year
$38.29
$4.34
P/E Ratio
N/A
$81.20
Revenue Growth
29.85
4.51
52 Week Low
$10.03
$3.74
52 Week High
$69.65
$6.45

Technical Indicators

Market Signals
Indicator
TNXP
III
Relative Strength Index (RSI) 57.23 50.82
Support Level $12.43 $3.95
Resistance Level $15.19 $4.37
Average True Range (ATR) 1.01 0.14
MACD 0.20 -0.01
Stochastic Oscillator 87.20 75.56

Price Performance

Historical Comparison
TNXP
III

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About III Information Services Group Inc.

Information Services Group Inc is an AI-centered technology research and advisory firm providing digital transformation and technology advisory services that help organizations optimize performance, reduce costs, and accelerate innovation. The Company's expertise includes sourcing advisory, cloud and data analytics, managed governance and risk services, network and software advisory, technology strategy and operations design, change management, and market intelligence, serving both private- and public-sector clients globally. It operates in one segment, fact-based sourcing advisory services, and operates principally in the Americas, with generate maximum revenue in Europe and the Asia Pacific.

Share on Social Networks: